Skip to Main Content

WASHINGTON — Sparks flew between a patient advocate and a drug industry representative. The middlemen and the manufacturers reached a strained detente. Statistics were offered and disputed, as were policy options both controversial and staid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!